BMO Capital Market analyst David J. Chiaverini and Richard Fellinger reiterate their Market Perform rating on Invesco Ltd. (NYSE:IVZ), below is their latest report.
Invesco 4Q13 earnings
Invesco Ltd. (NYSE:IVZ) reported 4Q13 adjusted EPS of $0.58 (BMO $0.55, cons. $0.57).
Q2 Hedge Funds Resource Page Now LIVE!!! Lives, Conferences, Slides And More [UPDATED 7/5 21:37 EST]
Simply click the menu below to perform sorting functions. This page was just created on 7/1/2020 we will be updating it on a very frequent basis over the next three months (usually at LEAST daily), please come back or bookmark the page. As always we REALLY really appreciate legal letters and tips on hedge funds Read More
Impact & analysis
P&L results were largely in line with our estimates, and the beat resulted from a lower than-expected tax rate and share count (management stepped up repurchases to $350mm in the quarter above our $50mm estimate). Longterm net inflows of $1B (+$0.3B active, +$0.7B passive) were much better than our estimate of $4B of outflows
In a stark contrast to recent trends, institutional flows (+$1.3B) outpaced retail (-$0.3B) in the quarter, as real estate and bank loan products continue to sell well in the institutional channel. All-in, alternative strategies (+$2.5B) saw the largest inflows during the quarter. Key takeaways include 1) following the announcement that Neil Woodford would be leaving (from Oct 15 to year-end), UK Equity Income had $4.8B of outflows, and management is optimistic existing clients will remain invested in the fund (or at least the franchise) including one public assurance from the Edinburgh Investment Trust (~$2B USD of AUM);
we continue to model $20B of outflows from the strategies as Woodford’s official departure date is at the end of April; 2) new product development was strong as Invesco Ltd. (NYSE:IVZ) launched more funds during the three months than any full calendar year over the past five years; strategies include the Global Total Return Funds and an expanded product suite in China; and 3) flows in balanced funds continue to struggle with $1B of outflows in 4Q13; increasing interest in risk-based assets is negatively affecting IBRA products.
Valuation & recommendation
Our 2014/2015 adjusted EPS estimates are unchanged at $2.40/$2.70. Our $36 price target is based on a sum- of- the- parts valuation (see page 2). We maintain our Market Perform rating owing to the remaining uncertainty surrounding Woodford’s upcoming departure.